Ayoxxa Closes on $4M in Funding to Continue Developing Label-Free Bead Array Platform | GenomeWeb

Biotech firm Ayoxxa Biosystems said this week that it has added a second closing to its Series A financing, bringing the round to a total of €3 million ($4 million). Also this week, it entered into a research collaboration agreement with the National University of Singapore.

The company aims with both moves to drive development and commercialization of its in situ encoded bead-based arrays, or IEBA, immunoassay platform, CEO Andreas Schmidt told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.